Covestor Ltd Acquires 133 Shares of Hologic, Inc. (NASDAQ:HOLX)

Covestor Ltd boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 23.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 692 shares of the medical equipment provider’s stock after acquiring an additional 133 shares during the quarter. Covestor Ltd’s holdings in Hologic were worth $56,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Prentiss Smith & Co. Inc. grew its holdings in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its stake in Hologic by 20.3% during the second quarter. Massmutual Trust Co. FSB ADV now owns 831 shares of the medical equipment provider’s stock worth $62,000 after buying an additional 140 shares during the last quarter. Wedmont Private Capital increased its holdings in shares of Hologic by 3.7% during the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock worth $361,000 after buying an additional 162 shares in the last quarter. Sequoia Financial Advisors LLC raised its stake in shares of Hologic by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after acquiring an additional 165 shares during the last quarter. Finally, Curbstone Financial Management Corp boosted its holdings in shares of Hologic by 0.9% in the 2nd quarter. Curbstone Financial Management Corp now owns 23,126 shares of the medical equipment provider’s stock worth $1,717,000 after acquiring an additional 200 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 2.1 %

NASDAQ:HOLX opened at $77.54 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12-month low of $67.59 and a 12-month high of $84.67. The firm has a market capitalization of $18.01 billion, a P/E ratio of 23.29, a P/E/G ratio of 2.52 and a beta of 0.98. The stock’s fifty day simple moving average is $80.77 and its 200-day simple moving average is $78.22.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same period last year, the firm posted $0.89 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently weighed in on HOLX. Evercore ISI raised their price target on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Stephens reaffirmed an “overweight” rating and issued a $92.00 price target on shares of Hologic in a report on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada increased their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.